Navigation Links
Generex Secures Commitments for $3.6M Capital Raise
Date:1/25/2012

WORCESTER, Mass. and TORONTO, Jan. 25, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) announced today that it has secured two commitments for an aggregate capital raise of CA$3,600,000.  This funding is structured as term loans of one year from private lenders secured by the Company's real estate.  Interest on the loans is payable monthly at the rate of 10% per annum.

"This capital infusion will permit the Company to advance its redevelopment plans, and to do so in a manner that is not dilutive to our stockholders," commented Mark Fletcher, Generex's President & Chief Executive Officer.

The first loan, for an aggregate of CA$2,500,000, closed on January 19, 2012.  A portion of the Company's real estate is subject to a prior ranking mortgage in the approximate amount of CA$1,100,000.  A portion of the first loan equal to that amount has been placed in escrow pending discharge of the prior ranking mortgage.

The second loan, for an aggregate of CA$1,100,000, is designed to discharge the prior ranking mortgage.  The second loan is scheduled to close on or before January 30, 2012, whereupon the escrowed portion of the first loan will be released to the Company.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
2. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
3. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
4. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
5. Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting
6. Generex Provides Update on Spinout of Antigen Express
7. Generex Augments Cash Position With Sales of Non-Essential Assets
8. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
9. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
10. Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America
11. Generex Provides Clarification of Facts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... ) has announced the addition of Jain PharmaBiotech,s ... Companies" to their offering. This ... as a characteristic that can be objectively measured ... or pathogenic processes as well as pharmacological responses ...
(Date:9/2/2015)... , September 2, 2015 ... the winners of the 2015 BeHEARD science challenge, a ... offers rare disease researchers, access to the latest life ... its drug repositioning and pathway analytics capability to support ... Nation Foundation in the study of Niemann-Pick Disease Type ...
(Date:9/2/2015)... 2, 2015 Australian prostate cancer technology company ... science prize recognising ,outstanding, science that uses its patented ... launch a novel prostate cancer diagnostic test known as ... consortium taking out the peer-reviewed Australian Museum Eureka Science ... This prize is awarded for ground breaking ...
(Date:9/2/2015)... 2015 BioLight Life Sciences ... "Company"), a firm that invests in, manages and ... announced today that presentations highlighting its IOPtiMate™ system ... at the Ophthalmology Futures European Forum and the ... & Refractive Surgeons ("ESCRS"), both taking place in ...
Breaking Biology Technology:Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
... InterMune, Inc. (Nasdaq: ITMN ) today announced ... matter patent which covers the ITMN-191 (R7227) compound. The ... ITMN-191 is an inhibitor of the hepatitis C virus (HCV) ... President of InterMune, said, "We are pleased to announce that ...
... Md., Feb. 19 Human Genome Sciences, Inc. (Nasdaq: ... sponsor a conference call to discuss its financial results ... results are expected to be disclosed on Thursday, February ... )The conference call will be hosted by ...
... era of specialized test for cardiac risk assessmentBIRMINGHAM, Ala., ... Pittsburgh Steelers, adding a heart-healthy supplement to their diet ... Bowl XLIII. That,s according to a clinical study proving ... football players. Findings were published January in the inaugural ...
Cached Biology Technology:InterMune Announces Issuance of U.S. Patent for ITMN-191 2InterMune Announces Issuance of U.S. Patent for ITMN-191 3Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results 2VAP Test Demonstrates Value of Fish Oil in Reducing Heart Risk for Super Bowl Champs 2VAP Test Demonstrates Value of Fish Oil in Reducing Heart Risk for Super Bowl Champs 3
(Date:8/25/2015)... LAKE CITY and BELLEVUE, Wash. ... global leader in advanced robotic systems, announced today it ... robotic unmanned ground vehicle (UGV), at the National Tactical ... City.  The Guardian S is the ... the culmination of years of research and in-field trials ...
(Date:8/20/2015)... Aug. 20, 2015 The wearable technology ... are active and healthy. However, wearable technology has ... environment to help improve diagnostic capabilities and therapeutic ... the Wearable Technologies Conference 2015 , where ... for wearables in healthcare.    "Over ...
(Date:8/19/2015)...  VOXX International Corporation (Nasdaq: VOXX ) ... Definitive Agreement to purchase the assets, inclusive of ... EyeLock through an acquiring entity.  Upon consummation of ... in the acquiring entity. The closing of the ...  Expanding on its existing supply chain and distribution ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... can improve the symptoms of children with autism was not ... found that eliminating gluten and casein from the diets of ... or bowel patterns. The study is the most ... on the difficult yet crucial task of ensuring participants received ...
... in 5 cases of infection with the potentially deadly fungus ... multiple strains of the pathogen. Researchers from the Institut ... findings today in the inaugural issue of mBio , ... for Microbiology. "Koch,s postulates are criteria establishing a causal ...
... researchers led by Jeffrey Peng, assistant professor of chemistry ... using Nuclear Magnetic Resonance (NMR), to move drug design ... and their targets. The research, which was published ... to the growing attention given toward the shape-shifting movement ...
Cached Biology News:Popular autism diet does not demonstrate behavioral improvement 2Popular autism diet does not demonstrate behavioral improvement 3Unexpectedly high rate of multiple strains in fungal infection 2Nuclear magnetic resonance aids in drug design 2
Request Info...
... Calmodulin Sepharose 4B, ... single-step purification of ... proteins.Purification of calmodulin-regulated ... eukaryotic cells. Category: ...
...
AdestaTM Tissue/Cell Preservation Medium Sterile / Non-sterile: Sterility Tested Endotoxin: ...
Biology Products: